Delivery Order SPE2DB20D3101-SPE2DB25FRUY8
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Tagrisso 80 mg tablets in quantities of 30, with a ceiling value of $10,662.57. This is a firm fixed-price delivery order with an ultimate completion date of August 11, 2025, and represents fulfillment of pharmaceutical needs for military and federal healthcare systems. The contract carries no set-aside designation, indicating it was competitively awarded....
- The Defense Logistics Agency awarded a delivery order valued at $31,987.71 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on August 27, 2025, with an ultimate completion date of September 18, 2025. This competitive award, with no set-aside designation, reflects firm fixed-price pricing terms and represents a pharmaceutical supply delivery to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) valued at $10,662.57. This firm fixed price delivery order, with an ultimate completion date of September 9, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation. AmerisourceBergen,...
- The Defense Logistics Agency awarded a delivery order valued at $53,312.85 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units). This firm fixed-price delivery order, issued on September 9, 2025, represents a competitively awarded contract with no set-aside designation and an ultimate completion date of September 30, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $42,155.20 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide TAGRISSO 80 MG TABLET 30S. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to...
- This delivery order, awarded on August 7, 2025, to AmerisourceBergen Drug Corp represents a $10,662.57 firm fixed-price contract for the supply of Tagrisso 80 mg tablets (30-count units) to the Defense Logistics Agency (DLA), a Defense Department component. The contract is competitively awarded with no set-aside designation and carries an ultimate completion date of August 28, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Tagrisso 80 mg tablets in a quantity of 30 units. This Firm Fixed Price delivery order carries a ceiling value of $10,662.57 and is scheduled for completion by August 18, 2025. The contract was competitively awarded with no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order operates...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $21,325.14 and an ultimate completion date of September 30, 2025. This non-set-aside competitive award represents a child delivery order placed against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The $10,662.57 delivery order contract is for the supply of the pharmaceutical product Tagrisso 80 mg tablet 30s. The contract is a firm fixed-price, non-set-aside award with a completion date of June 11, 2025. Amerisourcebergen Drug Corp holds a substantial $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,662.57 firm fixed-price contract is for the delivery of the prescription medication Tagrisso 80 mg tablets. The contract has an ultimate completion date of May 12, 2025 and is not set-aside. AmerisourceBergen Drug Corp holds a substantial $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRUY8Delivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for the supply of Tagrisso 80 mg tablets (30-count units) with a contract ceiling value of $10,662.57. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of October 1, 2025, awarded on September 10, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen supplies critical medications and medical commodities to support military healthcare programs globally. The company's contract portfolio with DLA demonstrates its role as a key supplier for the federal medical supply chain, providing pharmaceuticals ranging from generic to brand-name drugs across multiple therapeutic areas to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 9/10/25 |